FDA approve Lybalvi (olanzapine/samidorphan) for use in schizophrenia and bipolar I disorder in US
Samidorphan, an opioid antagonist was included in the makeup of the medication to control weight gain from olanzapine. Approval was based on data from the ENLIGHTEN studies which found similar antipsychotic efficacy, but reduced percentage of weight gain vs olanzapine alone.
Source:
Biospace Inc.